Capsules

The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive dyskinesia, according to a press release from the manufacturer.

The FDA has accepted a new drug application from Neurocrine Biosciences Inc. for its novel granule formulation of oral Ingrezza capsules, for those with tardive dyskinesia or chorea associated with Huntington’s disease.

Amneal Pharmaceuticals has received an abbreviated new drug application from the FDA for its lisdexamfetamine dimesylate capsules to treat ADHD in patients aged 6 years and older and moderate to severe binge-eating disorder in adults.

The FDA has approved the 20 mg version of nitisinone used to treat hereditary tyrosinemia, according to a press release.

Sun Pharmaceutical Industries received FDA approval of its abbreviated new drug application for mesalamine extended-release capsules indicated for use in ulcerative colitis, according to a press release.

LAS VEGAS — Fecal microbiota transplant capsules may improve cognition in patients with hepatic encephalopathy; however, results may vary by donor and recipient factors, according to a presentation at the ACG Annual Scientific Meeting. “FMT is likely safe with rigorous screening protocol, though some patient subgroups with very advanced cirrhosis and decompensated disease potentially warrant exclusion of this treatment,” Patricia P. Bloom, MD, transplant hepatologist from the University of Michigan, said during the presentation. “It is possible reversing rifaximin (Xifaxan, Salix Pharmaceuticals) resistance is another mechanism by which FMT is effective in this condition.”